Difference between revisions of "Nilutamide (Nilandron)"
Jump to navigation
Jump to search
m |
m |
||
| Line 19: | Line 19: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Endocrine therapy]] | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1996]] | ||
Revision as of 22:14, 8 November 2014
Also known as Anandron.
General information
Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Nilutamide (Nilandron) patient drug information (Chemocare)[3]
- Nilutamide (Nilandron) patient drug information (UpToDate)[4]